Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia
Hanren Dai(Anhui Medical University), Weidong Han(Zhejiang Cancer Hospital)
Cited by 320
Related Papers
LPS-preconditioned mesenchymal stromal cells modify macrophage polarization for resolution of chronic inflammation via exosome-shuttled let-7b
|Journal of Translational Medicine|2015|660
New development in CAR-T cell therapy
|Journal of Hematology & Oncology|2017|409
Lessons learned from the blockade of immune checkpoints in cancer immunotherapy
|Journal of Hematology & Oncology|2018|395
Chimeric Antigen Receptors Modified T-Cells for Cancer Therapy
|JNCI Journal of the National Cancer Institute|2016|300